pharma · EBV-induced Lymphomas · Coronary Artery Disease
Evidence Based Cataract
Evidence Based Cataract Study Group
Evidence Based Cataract is a pharma organization headquartered in THOUSAND OAKS, CA, CN. Primary therapeutic focus areas include EBV-induced Lymphomas, Coronary Artery Disease, Primary Progressive Multiple Sclerosis, Lup
THOUSAND OAKS, CA, CN HQ
NMPA registrant Type
Company details
- Status
- Public
- HQ
- THOUSAND OAKS, CA, CN
- Programs
- 10
- Drugs
- 8
- Patents
- 10
Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs)
Phase 2 · mab · EBV-induced Lymphomas
Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs) for EBV-induced Lymphomas is a Phase 2 program (mab) at Evidence Based Cataract Study Group with 1 ClinicalTrials.gov record(s).
Internal code 95-024
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Evidence Based Cataract Study Group
- Phase
- Phase 2
- Modality
- mab
- Indication
- EBV-induced Lymphomas
- Status
- completed
- Trials
- 1